CAR T-cells therapy has an obvious barrier in acute myeloid leukemia (AML) because myeloid-directed immunotherapy will eradicate normal as well as malignant cells, leading to bone marrow failure, as has been shown in several preclinical studies of CD33 or CD123 directed CAR T cell therapy [69, 70]. The gene discussed is CD33; the disease is acute myeloid leukemia.